Michael J. Dickinson, MBBS, DMedSc, on Non-Hodgkin Lymphoma: Early Study Findings With Novel T-Cell–Engaging Bispecific Antibody

July 07, 2020 By The ASCO Post Staff

Michael J. Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses phase I dose-escalation study results on CD20-TCB, which showed activity, including durable complete responses, and manageable safety in heavily pretreated patients with relapsed or refractory non-Hodgkin lymphoma (Abstract S241).

Related Content